Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Q3 FY26 Earnings Presentation
16 slides from Fermenta Biotech's earnings presentation, Feb 11, 2026
Slide 1: Intimation of Investor Presentation to BSE
Ref: F.No.: 908 February 11, 2026 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Investor Presentation – Q3/9moFY26 Ref: Scrip Code: 506414 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure
Slide 2: Fermenta Biotech Ltd Q3/9moFY26 presentation
Fermenta Biotech Ltd Q3/9moFY26 presentation 11 February 2026
Slide 3: Disclaimer
Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on t
Slide 4: Best-in-class, scientifically-validated nutritional ingredients
Fermenta provides best-in-class, scientifically-validated nutritional ingredients for the world’s leading brands in the pharmaceutical, dietary supplements, food and beverage, veterinary, and animal feed industries. Our edge? Decades of expertise in global-scale, complex manufacturing, and research-
Slide 5: Q3/9moFY26 Highlights
Q3/9moFY26 Highlights Financials (consolidated) with Real Estate Performance Q3FY26 9moFY26 • Human nutrition segment volumes grew 46% over 9MFY25 INR 140.5 crore INR 421.2 crore • Animal nutrition segment volumes grew 52% over Revenue 9MFY25 and average realization down by 8% over (down 11% YoY, up
Slide 6: Lines of Business
Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 - Human Vitamin D3 - Animal Others Premium supplements, food Specialized formulations for Customized Food Premixes, fortification, and pharmaceuticals livestock and pou
Slide 7: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) 9moFY26 9moFY25 YoY change Geographical Revenue Mix (INR crore) (INR crore) (%) (consolidated) excluding real estate value Nutrition Business unlocking Vitamin D3 – Human 230.8 152.8 +51% Nutrition 16% 0% 16% Vitamin D3 – Animal 85.5 58.7 +46% Nutrition 21% Others 24.1 31.
Slide 8: Cost Breakdown (Without Real Estate)
Cost Breakdown (Without Real Estate) Stable Costs amid Optimized Operating Leverage Raw material costs well-contained at 38% of revenue in (% of Revenue) 9moFY26, stable versus FY25 and a significant Cost Component 9moFY26 FY25 FY24 improvement from 53% in FY24, reflecting better procurement efficie
Slide 9: Customer Concentration (Without Real Estate)
Customer Concentration (Without Real Estate) Well-Diversified Base with Balanced Revenue Distribution Low single-customer dependency with the largest Mitigating concentration risk while building resilience customer contributing only 7% of total revenue. Only 3 through a balanced and diversified clie
Slide 10: The Opportunity
The Opportunity Leverage Fermenta’s strengths towards meeting evolving consumer needs and regulatory requirements across diverse markets India Global Innovation Drivers Preventive health awareness Nutritional supplements Nutrigenomics Growing middle class Aging drives vitamin D Natural/o
Slide 11: Fermenta's Value Proposition
Fermenta’s Value Proposition Society Contribute to global health and preventive care through nutritional ingredients Support life productivity across human and animal populations Address environmental challenges with custom and green chemistry solutions Best-in-class, science-backed Market leadershi
Slide 12: Manufacturing and R&D
Manufacturing and R&D Enzymes and APIs including Vitamin D3 Customized premix plant Dedicated Vitamin D3 with Kullu Certifications: WHO-GMP, USFDA, backward integration for Himachal Pradesh FSSC, HALAL, KOSHER, GAIN etc. cholesterol Collaboration with toll Multiple global regulatory Dahej manufactur
Slide 13: Strategic Partnership Ecosystem
Strategic Partnership Ecosystem The Collaboration Strategic Value Global healthcare company Vitamin D awareness campaigns Extends our reach to healthcare specializing in diagnostics, Print and audiovisual educational materials professionals and patients medical devices, and nutrition Premier food te
Slide 14: R&D Focus Areas & Achievements
R&D Focus Areas & Achievements Focus Key Achievements Future Directions API New products Commercialized 11 products including Vitamin Calcefediol commercialization K1, Cholesterol, Lanolin derivatives Process improvement Vitamin D3 analogs development Cost optimization for Vitamin K1 process Yield e
Slide 15: Example R&D Outcomes
Example R&D Outcomes Strategic Product Portfolio Will Drive Future Revenue Growth Spray-Dried Vitamin D3 VITADEE Green P Customized Premixes ✔ Plant-based Vitamin D3 with clean-label ✔ Equipped with advanced instrumentation and ✔ Patented 100,000 IU/g for vegan supplement markets pilot-scale equipme
Slide 16: Thank you
Thank you Sumesh Gandhi - CFO sumesh.gandhi@fermentabiotech.com Fermenta Biotech Ltd